Through the deal, HMS will operate as sole distributor of the ReWalk exoskeleton systems for individuals with spinal cord injuries in France. The deal includes both the ReWalk Personal and ReWalk Rehabilitation systems for home and clinical use, respectively.
“Our partnership with ReWalk is a real opportunity for HMS. We have been working for 30 years in the medical materials domain with people who have lost their mobility. We have always looked for innovative technologies in this domain, especially with the arrival of the 1st stand-up wheelchairs and, later, intelligent control systems. Our goal is to provide maximum autonomy to our customers in their everyday lives. The ReWalk 6.0 offers new medical and social opportunities to individuals with spinal cord injury. In signing this exclusive distribution contract with ReWalk, HMS will foster the arrival of this new technology throughout France. It is when I saw sparkles in the eyes and a large smile on the face of a young paraplegic man using a ReWalk system that I knew why I really wanted to provide this product in France,” Harmonie disability activity head Sébastien Chamereau said in a press release.
The distribution agreement will apply to all of HMS’ offices across France, Marlborough, Mass.-based ReWalk said.
“The partnership with HMS provides an ideal structure to allow paralyzed individuals throughout France the ability to walk again. Starting in 2011, Dr. Jacques Kerdraon at Kerpape demonstrated leadership and built data to show the value of this technology. As the product is now available for everyday use at home and in the community, HMS provides the resources, support structure and quality as a leading provider of products for injured individuals,” ReWalk chief commercial officer Jodi Gricci said in a prepared statement.
In June, ReWalk Robotics debuted the prototype of its Restore soft suit exoskeleton designed to aid stroke survivors.
The company presented the prototype alongside collaborators from Harvard University’s Wyss Institute for Biologically Inspired Engineering, and said it would focus on the suit as a “core company goal” for the fiscal year.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.